drugset
drugset / Trial / NCT05117632

ALTO-100 in MDD and/or PTSD

NCT05117632 ↗

Phase 2 Completed 245 enrolled Alto Neuroscience
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.

Timeline

Start
2021-12-20
Primary completion
2022-12-01
Completion
2022-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ALTO-100 Unknown — Oral

Indications

major depressive disorder post-traumatic stress disorder